Elizabeth A Shephard

List of Publications by Year in Descending Order

62 papers	2,427 citations	28 h-index	49 g-index
65 ext. papers	2,698 ext. citations	5.4 avg, IF	4.97 L-index

#	Paper	IF	Citations
62	Flavin-Containing Monooxygenase 1 Catalyzes the Production of Taurine from Hypotaurine. *Drug Metabolism and Disposition*, **2020**, 48, 378-385	4	17
61	Flavin-containing monooxygenases: new structures from old proteins. *Nature Structural and Molecular Biology*, **2020**, 27, 3-4	17.6	0
60	Flavin-containing monooxygenase 3 (FMO3): genetic variants and their consequences for drug metabolism and disease. *Xenobiotica*, **2020**, 50, 19-33	2	28
59	Endogenous Roles of Mammalian Flavin-Containing Monooxygenases. *Catalysts*, **2019**, 9, 1001	4	5
58	Effect of Flavin-Containing Monooxygenase Genotype, Mouse Strain, and Gender on Trimethylamine -oxide Production, Plasma Cholesterol Concentration, and an Index of Atherosclerosis. *Drug Metabolism and Disposition*, **2018**, 46, 20-25	4	24
57	Metabolic Biomarkers of Ageing in C57BL/6J Wild-Type and Flavin-Containing Monooxygenase 5 (FMO5)-Knockout Mice. *Frontiers in Molecular Biosciences*, **2018**, 5, 28	5.6	7
56	A highly sensitive liquid chromatography electrospray ionization mass spectrometry method for quantification of TMA, TMAO and creatinine in mouse urine. *MethodsX*, **2017**, 4, 310-319	1.9	12
55	Identification of Flavin-Containing Monooxygenase 5 (FMO5) as a Regulator of Glucose Homeostasis and a Potential Sensor of Gut Bacteria. *Drug Metabolism and Disposition*, **2017**, 45, 982-989	4	17
54	Drug metabolism by flavin-containing monooxygenases of human and mouse. *Expert Opinion on Drug Metabolism and Toxicology*, **2017**, 13, 167-181	5.5	59
53	The integration and interpretation of pharmacogenomics - a comparative study between the United States of America and Europe: towards better health care. *Drug Metabolism and Personalized Therapy*, **2016**, 31, 91-6	2	1
52	A guide to the identification of metabolites in NMR-based metabonomics/metabolomics experiments. *Computational and Structural Biotechnology Journal*, **2016**, 14, 135-53	6.8	184
51	Trimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease. *Drug Metabolism and Disposition*, **2016**, 44, 1839-1850	4	181
50	Clinical utility gene card for: Trimethylaminuria - update 2014. *European Journal of Human Genetics*, **2015**, 23,	5.3	20
49	The phenotype of a knockout mouse identifies flavin-containing monooxygenase 5 (FMO5) as a regulator of metabolic ageing. *Biochemical Pharmacology*, **2015**, 96, 267-77	6	32
48	Isolation and Culture of Mouse Hepatocytes: Gender-Specific Gene Expression Responses to Chemical Treatments. *Methods in Molecular Biology*, **2015**, 1250, 3-12	1.4	6
47	Relationships between flavin-containing mono-oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population. *British Journal of Clinical Pharmacology*, **2014**, 77, 839-51	3.8	17
46	The phenotype of a flavin-containing monooyxgenase knockout mouse implicates the drug-metabolizing enzyme FMO1 as a novel regulator of energy balance. *Biochemical Pharmacology* , **2014**, 90, 88-95	6	28

45	Pharmacogenetic testing in the UK clinical setting. *Lancet, The*, **2013**, 381, 1903	40	3
44	Clinical utility gene card for: trimethylaminuria. *European Journal of Human Genetics*, **2012**, 20,	5.3	10
43	Metabolism and pharmacokinetics of the anti-tuberculosis drug ethionamide in a flavin-containing monooxygenase null mouse. *Pharmaceuticals*, **2012**, 5, 1147-59	5.2	12
42	The potential of knockout mouse lines in defining the role of flavin-containing monooxygenases in drug metabolism. *Expert Opinion on Drug Metabolism and Toxicology*, **2010**, 6, 1083-94	5.5	15
41	Human flavin-containing monooxygenase 2.1 catalyzes oxygenation of the antitubercular drugs thiacetazone and ethionamide. *Drug Metabolism and Disposition*, **2009**, 37, 178-86	4	36
40	A novel mutation in the flavin-containing monooxygenase 3 gene (FMO3) of a Norwegian family causes trimethylaminuria. *Molecular Genetics and Metabolism*, **2009**, 98, 198-202	3.7	6
39	Deletion of the mouse Fmo1 gene results in enhanced pharmacological behavioural responses to imipramine. *Pharmacogenetics and Genomics*, **2009**, 19, 289-99	1.9	20
38	Effects of the Anticonvulsant, Valproate, on the Expression of Components of the Cytochrome-P-450-Mediated Monooxygenase System and Glutathione S-Transferases. *FEBS Journal* , **2008**, 231, 337-343		
37	Flavin-containing monooxygenases: mutations, disease and drug response. *Trends in Pharmacological Sciences*, **2008**, 29, 294-301	13.2	101
36	The potentially deleterious functional variant flavin-containing monooxygenase 2*1 is at high frequency throughout sub-Saharan Africa. *Pharmacogenetics and Genomics*, **2008**, 18, 877-86	1.9	37
35	Alternative promoters and repetitive DNA elements define the species-dependent tissue-specific expression of the FMO1 genes of human and mouse. *Biochemical Journal*, **2007**, 406, 491-9	3.8	26
34	Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3). *Pharmacogenetics and Genomics*, **2007**, 17, 827-39	1.9	27
33	Expression of Recombinant Flavin-Containing Monooxygenases in a Baculovirus/Insect Cell System. *Methods in Molecular Biology*, **2006**, 320, 39-59	1.4	
32	Mutation, polymorphism and perspectives for the future of human flavin-containing monooxygenase 3. *Mutation Research - Reviews in Mutation Research*, **2006**, 612, 165-171	7	32
31	Determination of Cellular Localization of Expression of Flavin-Containing Monooxygenase Genes in Mouse Tissues by In Situ Hybridization. *Methods in Molecular Biology*, **2006**, 320, 295-305	1.4	
30	Microinjection of Targeted Embryonic Stem Cells and Establishment of Knockout Mouse Lines for Fmo Genes. *Methods in Molecular Biology*, **2006**, 320, 329-341	1.4	
29	Transfection of Primary Cultures of Rat Hepatocytes. *Methods in Molecular Biology*, **2006**, 320, 273-282	1.4	1
28	Deletion of Genes From the Mouse Genome Using Cre/loxP Technology. *Methods in Molecular Biology*, **2006**, 320, 307-319	1.4	

27	Deletion of genes from the mouse genome using Cre/loxP technology. *Methods in Molecular Biology*, **2006**, 320, 307-19	1.4	8
26	Microinjection of targeted embryonic stem cells and establishment of knockout mouse lines for Fmo genes. *Methods in Molecular Biology*, **2006**, 320, 329-41	1.4	6
25	Cell-, tissue-, sex- and developmental stage-specific expression of mouse flavin-containing monooxygenases (Fmos). *Biochemical Pharmacology*, **2004**, 68, 73-83	6	91
24	Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. *Pharmacogenetics and Genomics*, **2004**, 14, 117-30		137
23	Trimethylaminuria and a human FMO3 mutation database. *Human Mutation*, **2003**, 22, 209-13	4.7	80
22	Genetic polymorphisms of flavin-containing monooxygenase (FMO). *Drug Metabolism Reviews*, **2002**, 34, 523-32	7	46
21	Transfection of liver in vivo by biolistic particle delivery: its use in the investigation of cytochrome P450 gene regulation. *Molecular Biotechnology*, **2002**, 20, 145-51	3	18
20	Xenobiotic induction of cytochrome P450 2B1 (CYP2B1) is mediated by the orphan nuclear receptor constitutive androstane receptor (CAR) and requires steroid co-activator 1 (SRC-1) and the transcription factor Sp1. *Biochemical Journal*, **2001**, 355, 71-8	3.8	55
19	Xenobiotic induction of cytochrome P450 2B1 (CYP2B1) is mediated by the orphan nuclear receptor constitutive androstane receptor (CAR) and requires steroid co-activator 1 (SRC-1) and the transcription factor Sp1. *Biochemical Journal*, **2001**, 355, 71-78	3.8	79
18	Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. *Biochemical Pharmacology*, **2001**, 62, 777-86	6	103
17	Orphan receptor promiscuity in the induction of cytochromes p450 by xenobiotics. *Journal of Biological Chemistry*, **2001**, 276, 12822-6	5.4	82
16	Pyruvate-induced long-term maintenance of glutathione s-transferase in rat hepatocyte cultures. *ATLA Alternatives To Laboratory Animals*, **2001**, 29, 335-46	2.1	2
15	Compound heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FM03) gene in patients with fish-odour syndrome. *Pharmacogenetics and Genomics*, **2000**, 10, 799-807		55
14	A novel mutation in the flavin-containing monooxygenase 3 gene, FM03, that causes fish-odour syndrome: activity of the mutant enzyme assessed by proton NMR spectroscopy. *Pharmacogenetics and Genomics*, **2000**, 10, 439-51		39
13	The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primates, encodes a truncated, nonfunctional protein. *Journal of Biological Chemistry*, **1998**, 273, 30599-607	5.4	100
12	Immortalized hepatocytes from transgenic mice. *Biochemical Society Transactions*, **1997**, 25, 42S	5.1	
11	Structural organization of the human flavin-containing monooxygenase 3 gene (FMO3), the favored candidate for fish-odor syndrome, determined directly from genomic DNA. *Genomics*, **1997**, 46, 260-7	4.3	47
10	Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome. *Nature Genetics*, **1997**, 17, 491-4	36.3	216

9	The molecular biology of the flavin-containing monooxygenases of man. *Chemico-Biological Interactions*, **1995**, 96, 17-32	5	125
8	Cell systems capable of sustaining phenobarbital induction by CYP2B genes. *Biochemical Society Transactions*, **1994**, 22, 120S	5.1	
7	Expression in a baculovirus system of a cDNA encoding human CYP2A6. *Biochemical Society Transactions*, **1994**, 22, 122S	5.1	1
6	Regulation of cytochrome P4502B2 gene expression. *Biochemical Society Transactions*, **1994**, 22, 125S	5.1	2
5	Maintenance and induction in co-cultured rat hepatocytes of components of the cytochrome P450-mediated mono-oxygenase. *Biochemical Pharmacology*, **1993**, 45, 1583-91	6	57
4	Quantification of cytochrome P450 reductase gene expression in human tissues. *Archives of Biochemistry and Biophysics*, **1992**, 294, 168-72	4.1	44
3	Localization of cytochrome P-450 gene expression in normal and diseased human liver by in situ hybridization of wax-embedded archival material. *Hepatology*, **1992**, 16, 682-7	11.2	38
2	Cloning and sequence analysis of a rat liver cDNA coding for a phenobarbital-inducible microheterogenous cytochrome P-450 variant: regulation of its messenger level by xenobiotics. *Gene*, **1983**, 26, 41-52	3.8	31
1	FMO1 catalyzes the production of taurine from hypotaurine		1